286 related articles for article (PubMed ID: 31324407)
41. Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk.
Ingueneau C; Hollstein T; Grenkowitz T; Ruidavets JB; Kassner U; Duparc T; Combes G; Perret B; Genoux A; Schumann F; Bobbert T; Steinhagen-Thiessen E; Martinez LO
Vascul Pharmacol; 2020 Dec; 135():106804. PubMed ID: 32987194
[TBL] [Abstract][Full Text] [Related]
42. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
43. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
[TBL] [Abstract][Full Text] [Related]
44. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
Korman M; Wisløff T
Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
[TBL] [Abstract][Full Text] [Related]
45. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
46. Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?
Qamar A; Libby P
Curr Cardiol Rep; 2019 Jun; 21(8):77. PubMed ID: 31250329
[TBL] [Abstract][Full Text] [Related]
47. Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany.
Koenig W; Lorenz ES; Beier L; Gouni-Berthold I
Clin Res Cardiol; 2024 Jun; 113(6):812-821. PubMed ID: 37603070
[TBL] [Abstract][Full Text] [Related]
48. Optimizing Post-Acute Coronary Syndrome Dyslipidemia Management: Insights from the North American Acute Coronary Syndrome Reflective III.
Alanezi M; Yan AT; Tan MK; Bourgeois R; Malek-Marzban P; Beharry R; Alkurtass S; Gyenes GT; Nadeau PL; Nwadiaro N; Jedrzkiewicz S; Gao D; Chandna H; Nelson WB; Goodman SG;
Cardiology; 2024; 149(3):266-274. PubMed ID: 38290490
[TBL] [Abstract][Full Text] [Related]
49. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.
Serban MC; Banach M; Mikhailidis DP
Expert Opin Pharmacother; 2016; 17(3):369-80. PubMed ID: 26559810
[TBL] [Abstract][Full Text] [Related]
50. PCSK9 inhibitors for treating hypercholesterolemia.
Pasta A; Cremonini AL; Pisciotta L; Buscaglia A; Porto I; Barra F; Ferrero S; Brunelli C; Rosa GM
Expert Opin Pharmacother; 2020 Feb; 21(3):353-363. PubMed ID: 31893957
[No Abstract] [Full Text] [Related]
51. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
Pradhan AD; Aday AW; Rose LM; Ridker PM
Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
[TBL] [Abstract][Full Text] [Related]
52. Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review.
Chang Y; Eom S; Kim M; Song TJ
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109734
[TBL] [Abstract][Full Text] [Related]
53. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors.
Rane PB; Patel J; Harrison DJ; Shepherd J; Leith A; Bailey H; Piercy J
Am J Cardiovasc Drugs; 2018 Apr; 18(2):103-108. PubMed ID: 28849360
[TBL] [Abstract][Full Text] [Related]
54. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
[TBL] [Abstract][Full Text] [Related]
55. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
Pirillo A; Catapano AL
Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
[TBL] [Abstract][Full Text] [Related]
56. Combined lipid-lowering therapy.
Karásek D
Vnitr Lek; 2019; 64(12):1177-1184. PubMed ID: 30704254
[TBL] [Abstract][Full Text] [Related]
57. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
58. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
Blaum C; Seiffert M; Goßling A; Kröger F; Bay B; Lorenz T; Braetz J; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Brunner FJ; Waldeyer C
Eur J Prev Cardiol; 2021 Mar; 28(1):47-56. PubMed ID: 33580772
[TBL] [Abstract][Full Text] [Related]
59. Lipid-lowering therapy: Guidelines to precision medicine.
Su X; Cheng Y; Chang D
Clin Chim Acta; 2021 Mar; 514():66-73. PubMed ID: 33359059
[TBL] [Abstract][Full Text] [Related]
60. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
De Ferrari GM; Perna GP; Nicosia A; Guasti L; Casu G; Cuccia C; Picco F; Strazzella C; Totaro R; Cercone S; Canullo L; Horack M; Lautsch D; Gitt AK; Di Biase M
J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):485-490. PubMed ID: 29917002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]